These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 3106585

  • 1. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Andriole GL, Sandlund JT, Miser JS, Arasi V, Linehan M, Magrath IT.
    J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
    [Abstract] [Full Text] [Related]

  • 2. [Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
    Iwasaku-Fujimoto M, Fujiwara F, Todo S, Morioka Y, Imashuku S.
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):403-6. PubMed ID: 2106836
    [Abstract] [Full Text] [Related]

  • 3. Clinical overview of mesna.
    Burkert H.
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():175-81. PubMed ID: 6414692
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
    Sakurai M, Saijo N, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Sano T, Suemasu K, Jett JR.
    Jpn J Clin Oncol; 1986 Jun; 16(2):153-6. PubMed ID: 3090314
    [Abstract] [Full Text] [Related]

  • 6. Cyclophosphamide and ifosfamide: role of uroprotective agents.
    Williams SD, Munshi N, Einhorn LH, Loehrer PJ.
    Cancer Invest; 1990 Jun; 8(2):269. PubMed ID: 2119246
    [No Abstract] [Full Text] [Related]

  • 7. [High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
    Marti C, Steiner R, Viollier AF.
    Schweiz Med Wochenschr; 1979 Dec 08; 109(47):1885-7. PubMed ID: 119317
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.
    Scheef W, Klein HO, Brock N, Burkert H, Günther U, Hoefer-Janker H, Mitrenga D, Schnitker J, Voigtmann R.
    Cancer Treat Rep; 1979 Mar 08; 63(3):501-5. PubMed ID: 106965
    [Abstract] [Full Text] [Related]

  • 10. Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis.
    Matz EL, Hsieh MH.
    Urology; 2017 Feb 08; 100():16-19. PubMed ID: 27566144
    [Abstract] [Full Text] [Related]

  • 11. Oral administration of mesna with ifosfamide.
    Goren MP.
    Semin Oncol; 1996 Jun 08; 23(3 Suppl 6):91-6. PubMed ID: 8677457
    [Abstract] [Full Text] [Related]

  • 12. The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.
    Brock N.
    Recent Results Cancer Res; 1980 Jun 08; 74():270-8. PubMed ID: 6777836
    [Abstract] [Full Text] [Related]

  • 13. Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study.
    Hows JM, Mehta A, Ward L, Woods K, Perez R, Gordon MY, Gordon-Smith EC.
    Br J Cancer; 1984 Dec 08; 50(6):753-6. PubMed ID: 6437430
    [Abstract] [Full Text] [Related]

  • 14. The use of sodium 2-mercaptoethane sulfonate to prevent cyclophosphamide cystitis.
    Ehrlich RM, Freedman A, Goldsobel AB, Stiehm ER.
    J Urol; 1984 May 08; 131(5):960-2. PubMed ID: 6423841
    [Abstract] [Full Text] [Related]

  • 15. [Evaluation of the benefits of sodium 2-mercaptoethane sulfonate (MESNA) therapy for children undergoing high-dose chemotherapy].
    Sato J, Takaue Y, Saito S, Okamoto Y, Hirao A, Shimizu T, Abe T, Watanabe T, Kawano Y, Ninomiya T.
    Rinsho Ketsueki; 1993 Jan 08; 34(1):7-12. PubMed ID: 8450612
    [Abstract] [Full Text] [Related]

  • 16. Prevention of further cyclophosphamide induced hemorrhagic cystitis by hyperbaric oxygen and mesna in guinea pigs.
    Korkmaz A, Oter S, Deveci S, Goksoy C, Bilgic H.
    J Urol; 2001 Sep 08; 166(3):1119-23. PubMed ID: 11490309
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552.
    Case DC, Anderson J, Ervin TJ, Gottlieb A.
    Med Pediatr Oncol; 1988 Sep 08; 16(3):182-6. PubMed ID: 3132591
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.